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Abstract
While there has been progress inmaking use of breath tests to guide clinical decisionmaking, the full
potential of exhaled breath analysis still remains to be exploited.Here we summarize some of the
reasonswhy this is the case, whatwe have done so far to overcome some of the existing obstacles, and
our vision of howwe think breath analysis will play amore prominent role in the coming years. In
particular, we envision that real-time high-resolutionmass spectrometrywill provide valuable
information in biomarker discovery studies. However, this can only be achieved by a coordinated
effort, using standardized equipment andmethods inmulti-center studies to eventually deliver
tangible advances in the field of breath analysis in a clinical setting. Concrete aspects such as sample
integrity, compound identification, quantification and standardization are discussed. Novel
secondary electrospray ionization developments with the aimof facilitating inter-groups comparisons
and biomarker validation studies are also presented.
1. Introduction
No patient will be surprised when the physician, faced
with some diagnostic hypothesis, requests a blood or
urine analysis to confirm or reject the suspected
diagnosis. However, analysis of breath specimens is far
less common, and surely would raise the eyebrows of
many patients who are confronted with such a request
for the first time. In this perspective paper, we
summarize why we think breath analysis may soon
be routinely used for clinical decisionmaking. Despite
the clear advantages that breath poses as an alternative
matrix, its full potential remains to be exploited.
Nonetheless, a handful of breath tests approved by
regulatory authorities already provides a flavor of what
the future holds [1]. For example, the 13C-urea breath
test for detection ofHelicobacter pylori [2, 3], the nitric
oxide (NO) breath test for monitoring asthma [4],
and the alkanes breath test for heart transplant
rejection [5].
2. Biomarker discovery: shortcomings and
suggested strategies to overcome them
Clinicians generally base their diagnostic decisions
on a ‘biological marker’ (biomarker), which can
be broadly defined as any characteristic which can be
measured repeatedly and accurately to indicate the
medical state of a patient [6]. The goal of many
clinical research projects is to identify biomarkers
associated with an underlying pathophysiological
mechanism, with the aim to help clinicians improve
the diagnostic process and ultimately also the treat-
ment and monitoring of diseases. Unfortunately,
despite thousands of biomarker-discovery-related
studies, less than a hundred biomarkers are used
in the clinical environment [7]. Over time, various
reasons have been given to explain this fact [7–10].
Here, we analyze some of them, with a focus on the
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2.1. Preserving the integrity of the sample: real-time
analysis
Since the early 1970s, when gas chromatography was
used for the separation and detection of∼250 different
components of human breath [11], several other
techniques were developed to analyze exhaled breath.
These techniques can be categorized into three major
groups based on their mode of operations: (i) mass
spectrometry (MS)- and ion mobility-based techni-
ques, (ii) chemical sensors-based techniques, and (iii)
spectroscopic techniques. Breath samples for these
techniques can either be used directly for immediate
analysis by a device (on-line sampling) or need to be
collected in a bag or tube (off-line sampling) [12–14].
One major problem with sample collection, pre-
concentration (a necessity for gas chromatography-
MS), and othermanipulation is that this may compro-
mise the integrity of the sample. This is not only a
problem afflicting gaseous samples, but also liquid
samples such as blood. For example, McLerran et al
[15, 16] reported on the bias introduced in serum
proteomic profiles as a result of subjecting the samples
to freeze-thaw cycles. In line with this, concerns about
thermal degradation of metabolites during analysis
have recently been raised [17]. One way around this
problem of compromising the sample is to perform
on-line sampling and real-time analysis, which over-
comes the abovementioned problems and, for exam-
ple, also render it possible to measure unstable
compounds. Prominent examples of real-time breath
analysis techniques are proton transfer reaction-MS
(PTR-MS) [18] and selected ionflow tube-MS (SIFT-MS)
[19]. Both of these techniques use chemical ionization
(CI) of analyte molecules via collision with reactant ions
in controlled and well-defined ion-molecule reactions at
reduced pressure. After reaction, both reactant and
product ions are quantifiedbydownstreammass spectro-
metry [20].
During recent years, we have concentrated on a
third alternative for real-time MS-based techniques
called secondary electrospray ionization-MS (SESI-MS)
[21]. In SESI-MS, trace analytes from gaseous samples
are ionized by interacting with the charges produced by
an electrospray plume at atmospheric pressure by a CI-
like mechanism [22–25]. The major advantages of SESI
are its high ionization efficiency and its flexibility, as it
can be interfaced with high-end commercial atmo-
spheric pressure ionization-mass spectrometers. As a
result of its advantages and convenience, several groups
have incorporated SESI-MS into their research activ-
ities [26–33].
2.2. Compound identification
Different combinations of endogenous volatile
organic compounds (VOCs) are responsible for the
‘smell’ of breath, which has been used for centuries to
diagnose diseases: the smell of acetone for diabetes, a
fishy smell for liver disorders, a urine-like smell for
kidney failure, or a sewer-like smell for lung abscesses.
There are also many examples where animals with
powerful olfactory system, such as dogs and rats, were
trained and then used to diagnose various cancers,
infectious and metabolic diseases as reviewed by
Bijland et al [34]. However, for breath analysis to be
useful in clinical practice, identification of various
components responsible for a characteristic smell is
absolutely necessary.
This is also reflected by the statement of Xia et al
[35], arguing that ‘Biomarkers must consist of positively
identified compounds. Unknowns or tentatively identi-
fied features cannot (and never will) be approved for clin-
ical laboratory testing’. We support this statement
and think that high-resolution mass spectrometry
(HRMS) with tandem MS (MS/MS) capabilities is
among the most powerful methods for unambiguous
compound identification. Complementary techniques
to real-time analysis, like UPLC-MS/MS of exhaled
breath condensate, are also very useful to characterize
breath metabolites [36–39]. The latter is especially
important to characterize isomeric structures that
are indistinguishable by real-time mass spectrometric
analysis.
To address the requirements of sensitivity and
separation power, we have opted to use commercially
available atmospheric pressure ionization-mass spec-
trometers like the Q Exactive Plus (Thermo Fisher).
Modern Orbitrap mass analyzers have limits of detec-
tion in the range of 500 fg (S/N100:1), amass accuracy
of 1 ppm, and a mass resolution up to 140 000
(at m/z=200 and a scan rate of 1.5 Hz). They also
possess fragmentation (i.e. MS/MS) capabilities to
assist compound identification. In addition, it offers
the possibility of operating in negative ion mode, cov-
ering complementary molecules as compared to posi-
tive ion mode (i.e. metabolites prone to deprotonate
such as fatty acids [40, 41]). We take advantage of this
powerful technology to couple it with SESI to provide
real-time breath analysiswith outstandingmass spectro-
metric performance [42, 43]. To the best of our knowl-
edge, this is the only available option to perform real-
time breath analysis using commercial equipment with
a mass resolution of >30 000 and on-line MS/MS for
compound identification. Figure 1 illustrates the bene-
fits of real-time breath analysis with high resolution (i.e.
∼55 000) andhighmass accuracy (i.e.<1 ppm).
2.3.Quantification
In clinical practice, decision making using the positive
or negative outcome of a test is often based on a cut-off
value of a parameter, whichmaximizes both sensitivity
and specificity of the test. Hence, it is imperative that
absolute concentration data is reported for positively
identified biomarkers [14, 35]. SIFT-MS delivers
accurate real-time quantitation of selected volatiles
with concentrations down to parts-per-billion. PTR-
MS provides semi-quantitative results, but at lower
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detection limits approaching low parts-per-trillion.
At the moment, determining absolute concentration
using SESI-MS is challenging (for different reasons,
such as dependence on the MS instrument used,
complex ionization mechanism, etc). Nevertheless,
quantification is feasible by constructing calibration
curves for a givenmass spectrometric set-up [44, 45].
2.4. Standardization
Standardization at all levels (e.g. instrumentation,
sampling strategies, data analysis, etc) is a critical
aspect that needs to be addressed collectively [46–49].
We echo one of the reviewers’ comments on this issue:
‘In order to achieve standardization we need to agree the
key performance indicators that we will adopt collectively
to apply to our instruments and methodologies, and it is
the lack of objective criteria in this work that detracts
from its impact’. For this reason, we put together an
interdisciplinary team of engineers and scientists over
the past few years in order to address this important
aspect. In a first stage, we developed a universal SESI
source, designed to maximize ionization efficiency
and to be compatible with commercial mass spectro-
meters [50]. The main goal being to offer the
possibility of upgrading high-resolutionmass spectro-
meters into sensitive real-time sniffers. This develop-
ment allowed us to showcase the power of SESI-
HRMS [51] and, more importantly, we learned what
improvements were required for this technique to be
broadly used: namely, reducing the background levels
and memory effects so as to properly identify low
volatility species, and easing operation and mainte-
nance procedures. For this reason, a fully redesigned
ionizer has been developed by Fossil Ion Technology
(FIT, Malaga, Spain). Two key requirements were
considered for this engineering endeavor: it had to be
easy to clean, and it would not use electrodes to control
the flow of ions, thereby reducing geocmain as high as
previous prototypes. This required a very careful fluid
mechanics design. For this reason, we developed a
numerical method to simulate the flows of gases and
ions within the ionization region. Compared with
previous numerical methods, the new method incor-
porates the exchange of kinetic momentum between
the ions and the neutral gases. Figure 2 shows a
numerical simulation of the ion source, whereby the
geometry and operational conditions (i.e. electric and
flow fields) have been fully optimized. An important
element that the simulation unveiled was the existence
of a toroidal vortex at the core of the ionization region
produced by the friction between the ions and neutral
gases. The numerical simulation allowed us to find the
optimal geometry to stabilize the toroidal vortex,
maximizing the ionization efficiency and the flow of
ions transferred to the MS. In addition, a fraction of
the gas is deflected backwards so that vapors released
Figure 1.High-resolution and high-accuracymass spectrometry assists for highmetabolome coverage and for compound
identification. Breathmass spectrumobtained by combining SESI and anOrbitrapmass analyzer. It illustrates howhigh resolution is
crucial to obtain clearly defined features (in this case four clear peaks at nominalm/z 139), as well as how highmass accuracy provides
nearly unambiguousmolecular formulae. The corresponding time-traces for four exhalation cycles are also shown.
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from the inner walls of the ionizer do not reach the
ionization region. This helps to reduce background
signals, which can otherwise be very high because the
temperature in the ionization region is limited by the
boiling point of the electrospray. This configuration,
which does not incorporate any internal electrode,
can be easily opened and reassembled for cleaning.
Figure 3 shows the resulting source (Super SESI, FIT)
as designed for Thermo instruments. Supplementary
figure S1 is available online at stacks.iop.org/JBR/12/
027113/mmedia and shows two Super SESI sources
that workwith the same principles, having very similar
internal geometries. The housing and the interface
with the MS differs to make it compatible with either
Thermo or Sciexmass spectrometers.
The sampling interface and associated exhalation
maneuvers are also critical aspects [52, 53]. For this
reason, the ion source comes with a sampling interface
in order to standardize all the technical and sampling
procedures. The subject exhales through a disposable
mouthpiece featuring a one-way valve that retains
saliva. Both the flow and exhalation pressure are
controlled. The subject keeps the pressure within
a comfortable range by monitoring an analogic man-
ometer. This helps to stabilize the pressure of opera-
tion, but humans are not particularly good at
regulating the pressure of their breath. Especially, peo-
ple with lung diseases, elderly people and infants can
have serious problems to provide a steady pressure.
For this reason, our ionization system incorporates a
Figure 2.Numericalmodeling assists optimization of SESI. Detail of the numerical simulation of an ion source (FIT, Spain), as
optimized for Thermo instruments. Left: Sectional view of the ionization core; Center: streamlines, and concentration profile of
molecules and ions introduced through the sample inlet.Right: Concentration profile ofmolecules released from the innerwalls of the
ionizer, and the corresponding ions.
Figure 3.Optimized SESI source compatible with commercialmass spectrometers. Left: Overall view of the source including the
breath sampling interface.Right: Details of the nano-electrospray system, an open view of the ionization chamber ready for cleaning,
and the interface to theMS.
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regulator that stabilizes the flowpassed into the ionizer
—matching that found in the numerical simulations
to be optimal—and keeps it constant. When the per-
son exhales, the pressure within the regulator increa-
ses, and an internal weight is lifted by this pressure. As
it slides up, it opens an aperture for some exhaled
breath to exit to the room, thus reducing the pres-
sure in the regulator. When the exhaled flow changes,
the aperture changes accordingly. As a result, the pres-
sure in the regulator and the flow of breath passed
to the ionizer are automatically stabilized. Figure 4
shows the complete on-line breath analysis set-up,
including the sample inlet regulation system and the
ion source interfaced to a high-resolution mass
spectrometer (Thermo).
2.5. Additional important factors in translation of
anymass spectrometric system to a clinical
environment
2.5.1. Human
Training: Our own experience is that, with highly
standardized equipment as the one presented here
(figure 4), there is no need for skilled mass spectro-
metrists to acquire routine breath analyses. This task is
now being taken over by research nurses, leavingmore
time to mass spectrometrists to interpret data and
performmore demanding tasks such as quantification
and compound identification.
Maintenance: Our experience is that little main-
tenance is needed, being the cleaning of the core of the
ion source the main task. We recommend doing the
operation at least every week. The fact that the core is
easily removable and can be sonicated, eases the
operation and can be accomplished in around 30 min.
Patient acuity: Our own experience, with hundreds
of subjects measured over the last years, is that patient
compliance with the breath test is very high. This
applies to children down to five years old, as well
as patients with severe lung diseases. The procedure is
certainly less invasive than routine spirometries,
which are sometimes difficult to accomplish.
Time per sample: every patient coming to our SESI-
HRMS premises is asked to provide around ten repli-
cate exhalations, whereby positive and negative ion
mode spectra are acquired. The total time spent is typi-
cally around 10 min.
2.5.2. Environmental
One of the limitations of HRMS is that the ultrahigh
mechanical precision of the ion path, and the very high
vacuum required, come at the expense of bulky
structures and pumping systems anchored to specia-
lized laboratories. HRMS has very restraining installa-
tion requirements that limit the possibilities of
performing large real-time breath analysis campaigns,
as the patients need to approach the SESI-HRMS
instrument. For this reason, in order to transport the
instrument to the patient, we are developing a rack
system that houses all the elements needed to perform
SESI-HRMS analysis on the road (supplementary
figure S2).
Figure 4.Complete system enabling real-time breath analysis by SESI-HRMS in a standardized fashion. The exhalation pressure is
monitoredwith an analogmanometer. In addition, the regulator features a variable opening that further stabilizes the pressure and the
flowpassed into the analyzer. Thisflowmatches the optimal one found by the numerical simulations (figure 2).
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Figure 5.Workflow aiming to bring breath biomarkers into clinical practice.Untargeted approach (∼4 years): the process starts in a
mono-center pilot study, whereby typically a case-control studywith limited sample sizes (n∼30–50 patients per arm) are conducted.
In this early exploratory phase, our approach is untargeted,meaning that we screen for differences of all detectablemetabolites, rather
than concentrating in a subset of expected alteredmetabolites. Thus, the subjects exhale into a standardized SESI-HRMS system in full
MSmode, both in positive and negative ionmode. In the same visit, the subjects provide a breath condensate (EBC) sample, which is
immediately stored at−80 °C;Once thefingerprinting for all subjects has been concludedwe conduct a rigorous statistical analysis to
highlight themost promisingmass spectral features, while controlling for false discovery rate. Typically, a subset of around 10 features
or predictors are used to construct a classificationmodel. The prediction accuracy of themodel is assessed via cross-validations,
estimating as a result of the classification performance parameters such as the area under the ROC curve. If themodel suggests that at
this point unknownmetabolites hold promise for diagnosis thenwe pull out the EBC samples collected previously and run classical
high performance liquid chromatography-HRMS to determine the structure of these unknownmetabolites. Retention time and
fragmentation spectra arematched against chemical standards to ensure high degree of confidence in compound identification.
Additionally, we run real-time tandemMS/MSanalysis to confirm that the on-line breathmeasurements also show themost
diagnostic fragments; once themetabolites have been annotated, we interpret them in their biological context and follows a calibration
procedure to estimate absolute quantification.Targeted approach (∼5 years): at this pointwe initiate a furthermulti-center validation
study. This is a targeted approachwhereby different centers across Switzerland and elsewhere using the same standardized
experimental and data analysis procedures confirmwhether or not the panel of∼10 exhaledmetabolites identified previously, truly
have classification power in real populations respecting the disease prevalence.Multi-omics approach (∼5 years): if the results in the
previous phase are positive, wewould thenmove to amore comprehensive validation strategy whereby genomics, transcriptomics,
proteomics and classicalmetabolomics approaches would be combined to provide a global understanding of why these exhaled
metabolites are indeed altered under certain pathophysiological conditions. Finally, this would lead to a newphasewhere approval
from regulatory authorities and commercializationwould be sought.
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2.5.3. Clinical
Infection control: Dealing with patients suspected of
suffering from an infection poses additional chal-
lenges. In our case, the exhaled air goes directly into
the exhaust of the building, rather than to the room.
Importantly, the only direct contact with the SESI
source is through a disposable mouthpiece. In addi-
tion, the fact that the ion source is easily cleanable
allows for rapid disinfection of the sampling tube and
ionization core.
Sample consumables: Consumables are restricted
to disposablemouthpieces and electrospray emitters.
Background volatiles: The new generation of ion
sources (figures 2–4) have been specifically designed to
minimize this issue: (i) the system operates at high
temperature, (ii) complex geometries vulnerable to
contamination have been eliminated, (iii) the ionizer
and sampling tube are coated with analytical grade
silica, (iv) contaminants released from the inner walls
of the system are carried away and not ionized, (v) the
electrospray region is constantly bathedwith high pur-
ity nitrogen, which in addition is passed through active
charcoal filter before entering the ionizer, minimizing
as a result the chemical noise. In addition, the ambient
air of the room is constantly renewed with filtered air.
In any case, we recommend excluding from the data
analysis known contaminants ubiquitously present in
mass spectrometry (e.g. polysiloxanes [54, 55]).
Matrix effects: Our experience is that ion suppres-
sion occurs when highly abundant exogenous species
are present in the oral cavity, depleting as a result the
available primary reactant ions. For this reason, our
protocol requires no food, drinks (except for water),
tooth brushing and chewing gum at least one hour
before the breath test, as well as to refrain from using
lipstick or other lipmoisturizers.
2.5.4. Operational
Reproducibility and quality control: Background che-
mical noise can be used for twofold purposes. Firstly, it
can be used as internal standard for locking the mass
range to achieve accuracies within 2 ppm. In addition,
because the electrospray is bathed constantly with
ultrapure nitrogen, the intensity profile is rather
constant, offering the opportunity to use it as an
objective measure of inter-day reproducibility. Devia-
tions of explained variance of the first score, after
principal component analysis, beyond+/−2 standard
deviations and coefficient of variations above 20%
should rise a warning about the quality of the spectra.
In classical liquid phase-based metabolomics, pooling
samples and injecting them at regular intervals is
common practice for quality control [56]. In the case
of gaseous samples like breath, this is impractical. For
this reason, we are currently developing a gas sample
delivery system, covering typical chemical species
found in breath. The idea is to introduce trace
amounts of vapors at known concentrations interca-
lated in between breath analyses.
Mean-time between failure: Occasional clogging of
the electrospray emitters can occur during operation,
which can usually be remedied quickly by increasing
the pressure of the ESI to 1 bar for 30 s. After around
ten days of operation ultrasonic capillary cleaning
might be required, however by using a set of multiple
emitters, only minimal downtime due to capillary
clogging can be expected.
2.5.5. Financial
The capital investment of a brand new mass spectro-
meter and a SESI source is in the order of 800 000 Eur.
Taking a reasonable life span of 5 years, and consider-
ing two shifts of 8 h (i.e. 16 h of breath tests per day),
we can estimate that the salaries of two full time
employed research nurses over five is in the order of
1 million Eur. This gives an investment figure of
1 800 000 Eur, and adding a 25% overheads sums
2 250 000 Eur over five years. Now, in five years one
could carry out 115 200 breath tests (i.e. 10 min per
breath test), which gives an estimation of 20 Eur per
breath test. In the case in which the annual salary of a
research nurse is in the order of 50 000 Eur, the final
figurewould be 14 Eur per test.
2.6. Follow-up studies beyond the pilot phase
One of the main limitations in biomarker discovery
efforts is that putative markers identified in pilot studies
are rarely validated in follow-up studies, contributing to
the notion that biomarker discovery should be addressed
in a more comprehensive manner. Our strategy foresees
to validate putative markers by independent groups.
Thus, we have established a network of users of
standardized SESI-HRMS in Switzerland (e.g. Zurich
Exhalomics network; http://hochschulmedizin.uzh.ch/
en/projekte/zurich-exhalomics/projekt-details.html).
More recently, groups in Peru (Pontifical Catholic
University of Peru) and Italy (National Cancer Institute)
have joined this endeavor, and two centers in China will
shortly be added, which opens exciting opportunities to
conduct multi-center studies for breath biomarker
validation. Obviously, our network is open for other
groups willing to participate. During the last years we
have concentrated on phenotyping respiratory diseases
such as chronic obstructive pulmonary disease (COPD)
[57] and obstructive sleep apnea (OSA) [58] by exhaled
breath analysis. These pilot studies, using a limited
number of patients, resulted in panels of exhaled
metabolites that serve to predict the presence or absence
of disease, but also allow to gain insight into pathophy-
siological aspects of the disease. We are currently
validating the prediction power of these metabolites in
completely independent larger cohorts of patients (typi-
cally including around 150 subjects). The results for
COPD are very encouraging (i.e. prediction accuracy in
the range of 75%), whereby complete series of dicar-
boxylic acids seem to play a major role [59, 60]. OSA
validation studies are currently ongoing. Similarly,
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following preliminary animal studies suggesting that
semi-volatile drugs and their metabolites can be tracked
in breath, mirroring plasma levels [61, 62], we are
currently validating these findings to determine the
feasibility of using breath analysis for therapeutic drug
monitoring in children. Moreover, the close collabora-
tion between clinicians and the experts in analytical
chemistrywill allow to characterize children’s respiratory
diseases by measuring other lung function parameters
(e.g. lung volumeandventilationhomogeneity) [63]with
exquisite precision, as we have also broad epidemiologi-
cal and lung physiological experts on-site. This informa-
tion, combined with information at the metabolic
level obtained from SESI-HRMS, will enable a more
comprehensive understanding on the pathophysiology
of respiratory diseases.
3. Conclusion
The comprehensive description of the human volatile
phenome has been a landmark for the community [64].
However, there are still many challenges to tackle before
thefield of exhaled breath analysis will be fully developed
and validated for clinical practice. For this reason, we feel
it is absolutely necessary that clinicians, analytical
scientists, bioinformaticians and engineers work closely
together in order to successfully develop a truly transla-
tional research strategy. We have taken important steps
in this direction over the last years, providing very
promising results using the SESI-HRMS technique in a
clinical context. We are currently bringing this program
to the next level by establishing standardized instrumen-
tation and procedures across research groups in the
Americas, Europe and Asia. Figure 5 summarizes our
comprehensive strategy, whereby untargeted pilot stu-
dies are subsequently validated. Unambiguous com-
pound identification will enable to pinpoint altered
metabolic pathways, that could explain the mechanistic
link between clinical symptoms and the observation of
derangement of exhaled metabolites. Furthermore, we
are planning to incorporate a multi-omics approach to
provide a broader mechanistic perspective. During the
final phase of the workflow, approval of the regulatory
authorities and commercialization will be sought, as
these are essential steps to translate the biomarkers into
clinical practice [65–67].
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